Clinical Trials
11 trialsNCT00427349 2023-07-05
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT04915144 2023-02-21
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
British Columbia Cancer Agency
Phase 2 Withdrawn
NCT00050349 2017-03-01
EPO906 in Carcinoid and Other Neuroendocrine Tumors
Novartis
Phase 2 Completed
NCT00869050 2016-07-25
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Phase 2 Completed
NCT00416767 2016-05-30
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT00227773 2015-10-08
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT00131911 2014-11-17
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00096083 2013-10-23
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Delcath Systems Inc.
Phase 2 Completed
NCT00027638 2013-06-18
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00075439 2013-06-04
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00466856 2012-05-18
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated